variables: 817010
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
817010 | Bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility who are aged 15 years and over | patients | 2023-12-05 11:52:01 | 2024-07-25 22:54:11 | 2017-2019 | 6308 | { "unit": "patients", "numDecimalPlaces": 0 } |
0 | nrr_15plus | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#nrr_15plus | 2 | major | Number of bacteriologically confirmed pulmonary tuberculosis patients with rifampicin susceptibility who are aged 15 years and over. Rifampicin is an antibiotic medication used primarily in the treatment of tuberculosis and other bacterial infections; it works by inhibiting the growth of bacteria. | Among new and previously treated patients that have confirmed pulmonary tuberculosis cases with results for rifampicin testing, number susceptible to rifampicin and who are aged 15 years and over | [] |
int | [] |
0cf3d652083ff8a2880ac7070602f421 | 11575ca0c22cdeda21483e624785b852 |